Novus Acquisition & Development Corp (OTC Pink: NDEV) (PINKSHEETS: NDEV) has appointed Andrea Lopez, MSM, AHFI as an Executive Board Member and the new CEO for its Medical Marijuana "MMJ" subsidiary Novus Medical Group, Inc. d/b/a Novus MedPlan, in which she will lead the company into healthcare medical plan and health insurance related services.
Ms. Lopez's fifteen year tenure of global operational experience has included many facets of compliance and roll out of the healthcare delivery processes. Specifically, creating and maintaining health care policies under the performance standards and scrutiny of Medicare, and Fortune 500 Companies. She is an active member of the Global Healthcare Anti-Fraud Network, the National Health Care Anti-Fraud Association, the European Healthcare Fraud & Corruption Network, and the Health Care Compliance Association.
As a member of the Board of Directors and CEO of Novus Medical Group, Inc. d/b/a Novus MedPlan, Ms. Lopez will develop a medical plan putting Novus on the path of a Health Care Insurance program called the "MedPlan Program". The MedPlan Program will seek to deliver a health insurance format to patients interested in using medical marijuana in the states where it is legal.
Frank Labrozzi, Novus' CEO states, "After reviewing Ms Lopez's credentials, especially her tenure at International SOS, Express Scripts and PCS (now owned by Caremark), where she developed and led enterprise-wide efforts at the executive level, rolled out global Health Care programs with tight internal controls, and detailed policies and procedures to mitigate risk, we knew her experience would prove invaluable to our team."
Andrea received both a Master of Science in Security Management (MSM) and a Bachelor of Science degree in Criminal Justice Administration from the prestigious Bellevue University. We welcome her to the Novus family.
Novus is comprised of seasoned Wall Street veterans that have focused its business model in the healthcare portion of the medical cannabis industry. Management and its proposed future Board of Directors areas of expertise will diversify in Healthcare, Physicians Education, Pharma R&D, Compliance and Business Development. NDEV will work as an outside developer's and since MMJ is not Federally approved it will not cultivate, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violates the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws.
For Investor Relations contact:
Main Tel: (855) 422-4463
Gary F. Labrozzi
Website: www.ndev.biz or www.novusqc.com
SOURCE: Novus Acquisition & Development Corp